Glenn Harvey
Illustrator
From this contributor
How long-read sequencing will transform neuroscience
New technology that delivers much more than a simple DNA sequence could have a major impact on brain research, enabling researchers to study transcript diversity, imprinting and more.
How long-read sequencing will transform neuroscience
What kind of autism research should we do, and where should we do it?
Researchers at INSAR 2023 need to discuss these questions and remember that the purpose of research may be different for different communities.
What kind of autism research should we do, and where should we do it?
New measure characterizes gender diversity in study participants
The Gender Self-Report could help autism researchers include more gender-diverse people across a range of ages and neurotypes in their work.
New measure characterizes gender diversity in study participants
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Debut drug for Rett syndrome at edge of approval
The U.S. Food and Drug Administration plans to make an approval decision on the first-ever drug for girls and women with Rett syndrome by 12 March.
Debut drug for Rett syndrome at edge of approval
Explore more from The Transmitter
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.